369 related articles for article (PubMed ID: 29253847)
1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.
Mathur VS; Kumar J; Crawford PW; Hait H; Sciascia T;
Am J Nephrol; 2017; 46(6):450-458. PubMed ID: 29253847
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
Weisshaar E; Szepietowski JC; Bernhard JD; Hait H; Legat FJ; Nattkemper L; Reich A; Sadoghi B; Sciascia TR; Zeidler C; Yosipovitch G; Ständer S
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):453-461. PubMed ID: 34780095
[TBL] [Abstract][Full Text] [Related]
3. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications.
Elmariah S; Chisolm S; Sciascia T; Kwatra SG
JAAD Int; 2022 Jun; 7():156-163. PubMed ID: 35497636
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.
Hawi A; Alcorn H; Berg J; Hines C; Hait H; Sciascia T
BMC Nephrol; 2015 Apr; 16():47. PubMed ID: 25885112
[TBL] [Abstract][Full Text] [Related]
8. Anti-pruritic effect of nemolizumab in hemodialysis patients with uremic pruritus: a phase II, randomized, double-blind, placebo-controlled clinical study.
Kinugasa E; Igawa K; Shimada H; Kondo M; Funakoshi S; Imada N; Itami N; Fukazawa N; Takubo R; Kawata Y; Murota H
Clin Exp Nephrol; 2021 Aug; 25(8):875-884. PubMed ID: 33754202
[TBL] [Abstract][Full Text] [Related]
9. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
10. Intravenous nalbuphine 50 microg x kg(-1) is ineffective for opioid-induced pruritus in pediatrics.
Nakatsuka N; Minogue SC; Lim J; Montgomery CJ; Court CA; Malherbe S; Csanyi-Fritz Y; Kearney RA; Phillips L; Reid K; Kingsley J; Ansermino JM
Can J Anaesth; 2006 Nov; 53(11):1103-10. PubMed ID: 17079637
[TBL] [Abstract][Full Text] [Related]
11. Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis.
Maher TM; Avram C; Bortey E; Hart SP; Hirani N; Molyneux PL; Porter JC; Smith JA; Sciascia T
NEJM Evid; 2023 Aug; 2(8):EVIDoa2300083. PubMed ID: 38320144
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
13. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature.
Jannuzzi RG
Clin J Pain; 2016 Jan; 32(1):87-93. PubMed ID: 26650717
[TBL] [Abstract][Full Text] [Related]
14. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.
Fishbane S; Mathur V; Germain MJ; Shirazian S; Bhaduri S; Munera C; Spencer RH; Menzaghi F;
Kidney Int Rep; 2020 May; 5(5):600-610. PubMed ID: 32405581
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.
Pauli-Magnus C; Mikus G; Alscher DM; Kirschner T; Nagel W; Gugeler N; Risler T; Berger ED; Kuhlmann U; Mettang T
J Am Soc Nephrol; 2000 Mar; 11(3):514-519. PubMed ID: 10703675
[TBL] [Abstract][Full Text] [Related]
16. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
17. Treatment of intrathecal morphine-induced pruritus following caesarean section.
Alhashemi JA; Crosby ET; Grodecki W; Duffy PJ; Hull KA; Gallant C
Can J Anaesth; 1997 Oct; 44(10):1060-5. PubMed ID: 9350364
[TBL] [Abstract][Full Text] [Related]
18. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
19. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain.
Gear RW; Miaskowski C; Gordon NC; Paul SM; Heller PH; Levine JD
Pain; 1999 Nov; 83(2):339-45. PubMed ID: 10534607
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled clinical trial comparing the efficacy of dead sea mineral-enriched body lotion versus two types of placebo in the treatment of cutaneous dryness, itching, peeling and tightness in hemodialysis patients (EDIT).
Boaz M; Shtendik L; Oron M; Portugal-Cohen M; Kohen R; Biro A; Cernes R; Barnea Z; Maor Z; Katzir Z
Nephron Clin Pract; 2009; 113(3):c169-76. PubMed ID: 19672115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
